Sidley represented IDG Capital as the lead investor in HiFiBiO Therapeutics’ US$67 million Series C Financing. HiFiBiO Therapeutics is a global biotech company focused on mobilizing the human immune system to combat disease. IDG Capital led the round with the support of new investors, including Kite Pharma, Delian Capital and Hanne Capital. Existing investors who supported this round included Sequoia Capital China, VI Ventures, Legend Star Capital and LYFE Capital.
The Sidley team was led by partner Ruchun Ji (Shanghai) with assistance from partners Lei Li (Beijing and Shanghai), Thomas Duley (San Francisco) and Samuel Tiu (Los Angeles), counsel Stephen Arbreu, as well as associates Calamus Huang and Henry Cao.
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.
You have successfully set your edition to United States. Would you like to make this selection your default edition?
*Selecting a default edition will set a cookie.
This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly.
Necessary Cookies
The website cannot function properly without these necessary cookies, and they can only be disabled by changing your browser preferences. To learn more about these cookies, how we use them on our website, and how to revise your cookie settings, please view our cookie policy.